Skip to main
  1. Stocks
  2. Rhythm Pharmaceuticals
  3. Forecast
RYTM

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals (RYTM) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 43%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Rhythm Pharmaceuticals is positioned for durable growth because IMCIVREE is gaining traction in acquired hypothalamic obesity, with 3Q26 revenue of $92.1M, U.S. sales of $67.5M, and more than 700 patient start forms supported by expanding access and over 500 prescribers. Its outlook is further strengthened by an accretive LG Chem royalty buydown that cuts MC4R royalties to a flat 1% and by a $750M term loan facility that adds non-dilutive capital while preserving flexibility, with $320.9M in cash at 3Q26 and funding for at least 24 months. Beyond the launch, the company has multiple upside drivers from bivamelagon and RM-718, including planned Phase 3 PWS development in 2027 and Japan and Europe expansion, which broadens the long-term MC4R franchise opportunity.

Bears say

Rhythm Pharmaceuticals is facing a cautious fundamental setup because downside risk is concentrated in launch execution, with delays in outside-U.S. aHO launches and slower-than-anticipated uptake or reimbursement capable of materially pressuring revenue growth. The outlook is also weakened by execution risk around its next-generation MC4R programs, since delays or failure to develop competitive bivamelagon and RM-718 would leave the company overly dependent on IMCIVREE and limit long-term product diversification. Near-term estimates for 2027 and 2028 were reduced as topline was trimmed for a slower launch trajectory and operating expense increased, mainly due to milestone payments owed to LG Chem after the royalty amendment.

Rhythm Pharmaceuticals (RYTM) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rhythm Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Rhythm Pharmaceuticals (RYTM) Analyst Forecast & Price Prediction

Get the latest Rhythm Pharmaceuticals (RYTM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rhythm Pharmaceuticals (RYTM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rhythm Pharmaceuticals (RYTM) Forecast

Analysts have given Rhythm Pharmaceuticals (RYTM) a Buy based on their latest research and market trends.

According to 14 analysts, Rhythm Pharmaceuticals (RYTM) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $143, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $143, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rhythm Pharmaceuticals (RYTM)


Rhythm Pharmaceuticals (RYTM) Analyst Forecast & Price Prediction

Get the latest Rhythm Pharmaceuticals (RYTM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Rhythm Pharmaceuticals (RYTM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RYTM stock data and trends